# The RAS, Fibrinolysis and Cardiopulmonary Bypass

> **NCT00607672** · PHASE4 · COMPLETED · sponsor: **Vanderbilt University** · enrollment: 111 (actual)

## Conditions studied

- Coronary Artery Disease
- Angiotensin Converting Enzyme
- Angiotensin Receptor Blockers
- Cardiopulmonary Bypass
- Fibrinolysis
- Inflammation

## Interventions

- **DRUG:** Placebo
- **DRUG:** Ramipril
- **DRUG:** Candesartan

## Key facts

- **NCT ID:** NCT00607672
- **Lead sponsor:** Vanderbilt University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2011-08
- **Final completion:** 2011-12
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2012-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00607672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00607672, "The RAS, Fibrinolysis and Cardiopulmonary Bypass". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00607672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*